ENTA Stock — Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc (ENTA)

Updated October 16, 2026.

ENTA is a Stock. Total return is -35.4% over the past 13.6 years, 556.8 points behind SPY at 521.4%.

Enanta Pharmaceuticals is a biotechnology company that discovers and develops small molecule drugs for virology and immunology indications, with a pipeline including treatments for hepatitis B and C, respiratory syncytial virus, human coronaviruses, atopic dermatitis, and chronic spontaneous urticaria, along with a collaborative agreement with Abbott Laboratories for HCV protease inhibitor compounds. The company does not currently have an established distribution schedule. This security appeals primarily to growth-oriented investors interested in early-stage pharmaceutical development rather than those seeking current income.

ENTA performance versus SPY

Price and return data through 2026-10-16.

Total return is -35.4% over the past 13.6 years, 556.8 points behind SPY at 521.4%. Over the past year its total return — price change plus distributions reinvested — is -2.5%. Its deepest 1-year drawdown was 34.3%.

ENTA key facts

Asset type

Stock

Asset class

Equity

Inception date

03/21/2013

Distribution frequency

None

Last close

$11.10 (as of 2026-10-16)

Market cap

$323,291,962

Average volume

215412.0

Beta

0.963

Payout ratio

0.0%

Forward P/E

44.0529

EPS

$-2.46

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ENTA risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 34.3%.

Who may consider ENTA — and who may not

It is a weaker fit for investors who need monthly cash flow (ENTA does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ENTA

• All tickers starting with E

Tagged: Healthcare.

Frequently asked questions